IL1B and Alzheimer disease: Novel quinazolinone-based derivatives show MT anti-AD activity, exhibiting cholinesterase inhibitory and anti-inflammatory properties, with additional effects on hippocampal inflammatory markers (TNF-α, NFĸB, IL-1β, IL-6), antioxidant markers (SOD), and neuroprotection [156].